We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study
Read MoreHide Full Article
Shares of Galapagos NV (GLPG - Free Report) , a clinical-stage company, are rising in the premarket hours on Aug 23, after the FDA cleared its investigational new drug application to begin an early to mid-stage study of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL).
GLPG5101 is an autologous CD19 CAR-T cell therapy product candidate, which is administered as a single, fixed, intravenous dose. It has been developed utilizing Galapagos’ proprietary decentralized cell therapy manufacturing platform.
The planned phase I/II ATALANTA-1 study will evaluate the feasibility, safety and efficacy of GLPG5101 for the R/R NHL indication in the United States. Please note that the ATALANTA-1 study is currently ongoing in the EU for the same indication, and early data from the study have shown encouraging results.
The main goal of the phase I portion of the ATALANTA-1 trial is to assess the safety and initial effectiveness of GLPG5101 to establish the appropriate dosage strength for the phase II portion. Additionally, the phase I portion will also evaluate the efficacy and feasibility of decentralized manufacturing of GLPG5101 as a secondary objective.
On the other hand, the primary goal of the phase II portion is to assess the objective response rate, while secondary goals include evaluating the complete response rate, duration of response, progression-free survival, overall survival, safety, pharmacokinetics and the feasibility of decentralized manufacturing. The treatment period for all enrolled patients will be 24 months. Year to date, shares of GLPG have plunged 38.8% against the industry’s 1.6% growth.
Image Source: Zacks Investment Research
Per Galapagos, NHL is a type of cancer that originates in the lymphatic system, which is part of the body’s immune system. It involves the abnormal growth of lymphocytes, a type of white blood cell that plays a crucial role in fighting infections. All age groups are susceptible to NHL, although it most commonly occurs in adults more than 50 years of age. NHL is broadly classified into two types — aggressive (fast-growing) and indolent (slow-growing).
Galapagos has a deep pipeline of best-in-class small molecules and cell therapies in oncology and immunology. Under oncology, apart from GLPG5101, the company is currently evaluating two other candidates in separate clinical studies for leukemia and myeloma. Under immunology, Galapagos is developing investigational TYK2 inhibitor, GLPG3667, in separate mid-stage studies to treat lupus and dermatomyositis.
In the past 60 days, the consensus estimate for Arcturus Therapeutics’ 2024 loss per share has narrowed from $4.39 to $2.60. The estimate for 2025 is currently pegged at an earnings of 21 cents per share. Year to date, shares of Arcturus Therapeutics have lost 31.9%.
Earnings of Arcturus Therapeutics beat estimates in each of the last four quarters. ARCT delivered a four-quarter average earnings surprise of 56.73%.
In the past 60 days, the consensus estimate for Bioventus’ 2024 earnings per share has risen from 27 cents to 40 cents. The estimate for 2025 has increased from 43 cents to 45 cents during the same period. Year to date, shares of Bioventus have surged 87.5%.
BVS beat estimates in three of the last four quarters and missed the mark on one occasion, delivering an average earnings surprise of 102.86%.
In the past 60 days, the consensus estimate for Fulcrum Therapeutics’ 2024 loss per share has narrowed from $1.24 to 48 cents. The loss estimate for 2025 has narrowed from $1.71 to $1.51 during the same period. Year to date, shares of Fulcrum Therapeutics have jumped 30.2%.
FULC beat estimates in each of the last four quarters, delivering an average earnings surprise of 393.18%.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study
Shares of Galapagos NV (GLPG - Free Report) , a clinical-stage company, are rising in the premarket hours on Aug 23, after the FDA cleared its investigational new drug application to begin an early to mid-stage study of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL).
GLPG5101 is an autologous CD19 CAR-T cell therapy product candidate, which is administered as a single, fixed, intravenous dose. It has been developed utilizing Galapagos’ proprietary decentralized cell therapy manufacturing platform.
The planned phase I/II ATALANTA-1 study will evaluate the feasibility, safety and efficacy of GLPG5101 for the R/R NHL indication in the United States. Please note that the ATALANTA-1 study is currently ongoing in the EU for the same indication, and early data from the study have shown encouraging results.
The main goal of the phase I portion of the ATALANTA-1 trial is to assess the safety and initial effectiveness of GLPG5101 to establish the appropriate dosage strength for the phase II portion. Additionally, the phase I portion will also evaluate the efficacy and feasibility of decentralized manufacturing of GLPG5101 as a secondary objective.
On the other hand, the primary goal of the phase II portion is to assess the objective response rate, while secondary goals include evaluating the complete response rate, duration of response, progression-free survival, overall survival, safety, pharmacokinetics and the feasibility of decentralized manufacturing. The treatment period for all enrolled patients will be 24 months. Year to date, shares of GLPG have plunged 38.8% against the industry’s 1.6% growth.
Image Source: Zacks Investment Research
Per Galapagos, NHL is a type of cancer that originates in the lymphatic system, which is part of the body’s immune system. It involves the abnormal growth of lymphocytes, a type of white blood cell that plays a crucial role in fighting infections. All age groups are susceptible to NHL, although it most commonly occurs in adults more than 50 years of age. NHL is broadly classified into two types — aggressive (fast-growing) and indolent (slow-growing).
Galapagos has a deep pipeline of best-in-class small molecules and cell therapies in oncology and immunology. Under oncology, apart from GLPG5101, the company is currently evaluating two other candidates in separate clinical studies for leukemia and myeloma. Under immunology, Galapagos is developing investigational TYK2 inhibitor, GLPG3667, in separate mid-stage studies to treat lupus and dermatomyositis.
Galapagos NV Price and Consensus
Galapagos NV price-consensus-chart | Galapagos NV Quote
Zacks Rank & Key Picks
Galapagos currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the overall healthcare sector include Arcturus Therapeutics (ARCT - Free Report) , Bioventus (BVS - Free Report) and Fulcrum Therapeutics (FULC - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, the consensus estimate for Arcturus Therapeutics’ 2024 loss per share has narrowed from $4.39 to $2.60. The estimate for 2025 is currently pegged at an earnings of 21 cents per share. Year to date, shares of Arcturus Therapeutics have lost 31.9%.
Earnings of Arcturus Therapeutics beat estimates in each of the last four quarters. ARCT delivered a four-quarter average earnings surprise of 56.73%.
In the past 60 days, the consensus estimate for Bioventus’ 2024 earnings per share has risen from 27 cents to 40 cents. The estimate for 2025 has increased from 43 cents to 45 cents during the same period. Year to date, shares of Bioventus have surged 87.5%.
BVS beat estimates in three of the last four quarters and missed the mark on one occasion, delivering an average earnings surprise of 102.86%.
In the past 60 days, the consensus estimate for Fulcrum Therapeutics’ 2024 loss per share has narrowed from $1.24 to 48 cents. The loss estimate for 2025 has narrowed from $1.71 to $1.51 during the same period. Year to date, shares of Fulcrum Therapeutics have jumped 30.2%.
FULC beat estimates in each of the last four quarters, delivering an average earnings surprise of 393.18%.